Targeting signaling pathways to improve treatment for pancreatic cancer
Official title: Project 2: Targeting signaling networks to overcome therapeutic resistance in pancreatic cancer
Funded at Salk Institute for Biological Studies · NIH-10883563 · Data updated 2026-11-12
This study is looking at how certain signals in pancreatic cancer cells might help the cancer grow and resist treatment, with the goal of finding new ways to improve care for patients like you.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Salk Institute for Biological Studies NIH-funded |
| Lab location | 1 site (La Jolla, UNITED STATES) |
| Project start | July 6, 2023 |
| Project end | June 30, 2028 |
| Funding year | 2024 |
| Award (this year) | $472,698 |
| NIH project number | 5P01CA265762-02 |
| Project ID | NIH-10883563 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with pancreatic ductal adenocarcinoma, particularly those at advanced stages of the disease.
✕Less likely to help
Patients with early-stage pancreatic cancer or those with other types of cancer may not benefit from this specific research.
What this research studies
This research focuses on pancreatic ductal adenocarcinoma (PDA), a type of cancer that is often diagnosed at advanced stages and is resistant to standard treatments. The team aims to understand how certain signaling molecules, particularly those involving the STAT3 pathway, contribute to the cancer's growth and resistance to therapy. By using advanced techniques to analyze how these signals operate in both tumor cells and the surrounding immune environment, the researchers hope to identify new therapeutic strategies that can prevent resistance and improve patient outcomes. The study will involve both laboratory models and analysis of human patient samples to validate findings.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for pancreatic cancer, potentially improving survival rates and quality of life for patients.
How similar studies have gone: Previous research has shown promise in targeting similar signaling pathways in other cancers, suggesting that this approach may also be effective in pancreatic cancer.
Where this research is happening
-
Salk Institute for Biological Studies
La Jolla, United States Active
Researchers
- Principal investigator: Hunter, Tony R. — Salk Institute for Biological Studies
- Study coordinator: Hunter, Tony R.
Related research
Other NIH-funded projects on the same topics.
-
Microbial Dysbiosis and Its Role in Pancreatic Cancer
A doctor-researcher team at Northwestern University is studying how gut bacteria influence pancreatic cancer and its response to immunotherapy to find new ways to help patients.
-
Targeting aberrant enhancer landscapes in pancreatic cancer
A patient-facing look at a project that aims to understand how pancreatic cancer changes its cell identity and what that means for treatment.
-
Exosome-based microRNA biomarkers for early, non-invasive detection of pancreatic cancer
A study to develop a blood test that uses tiny RNA signals in exosomes to detect pancreatic cancer early, aiming to help people at risk or with early disease.
-
Exosome-based microRNA biomarkers for early detection of pancreatic cancer
A patient-friendly look at a study using tiny blood-based RNA markers inside exosomes to catch pancreatic cancer early without invasive procedures.
-
Programmable implanted living materials to fight pancreatic cancer
A patient-facing program will explore a safe, implantable living material that delivers sequential immunotherapies directly to pancreatic tumors to help fight cancer.
-
Targeting how platelets and pancreatic cancer talk to each other
A study exploring whether blocking the interaction between platelets and pancreatic cancer cells could slow cancer growth and spread and help identify new biomarkers.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.